|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Hematology Division, Ospedali Riuniti,
Bergamo; and the Mario Negri Institute for Pharmacological Research,
Consorzio Mario Negri Sud, S. Maria Imbaro, Italy.
Thrombohemorrhagic complications are a major cause of morbidity and
mortality in patients with essential thrombocythemia (ET) and
polycythemia vera (PV). The pathogenesis of these complications is not
completely clarified. Several studies have described abnormalities of
red blood cells and platelets in these patients. However, no studies
are available on changes in the polymorphonuclear leukocytes (PMNs),
which can play an important role in the activation of the hemostatic
system. In patients with ET (n = 37) and PV (n = 34), a series of
PMN activation parameters (PMN membrane CD11b and leukocyte alkaline
phosphatase [LAP] antigen expression, cellular elastase content,
plasma elastase, and myeloperoxidase levels) was evaluated
simultaneously with the levels of plasma markers of endothelial damage
(thrombomodulin and von Willebrand factor antigen) and hypercoagulation
(thrombin-antithrombin complex, prothrombin fragment 1 + 2, and
D-dimer). The results show the occurrence of PMN activation in both
groups of patients compared with a control group of healthy subjects.
An increase in CD11b and LAP expression by PMN membrane was observed,
together with a significant increase in cellular elastase content,
plasma elastase, and myeloperoxidase levels. In addition, patients had
high plasma levels of endothelial and hypercoagulation markers compared
with controls. For the first time, these data show that in ET and PV, 2 hematologic conditions that place patients at increased risk for
thrombosis, an in vivo leukocyte activation occurs and is associated
with laboratory signs of endothelium and coagulation system activation.
(Blood. 2000;96:4261-4266) Essential thrombocythemia (ET) and polycythemia
vera (PV) are chronic myeloproliferative disorders that share common
pathogenetic abnormalities of bone marrow stem cell proliferation. A
typical feature of ET and PV is a hemostatic imbalance resulting in
increased risk for both thrombotic and hemorrhagic
events.1 Arterial and venous thromboembolism are the major
causes of morbidity and mortality in these patients (approximately
40%).2 These events have been attributed to quantitative
and qualitative abnormalities of red blood cells and platelets arising
from the clonal rearrangement of hematopoietic cells. The relevance of
uncontrolled polycythemia as a risk factor for thrombosis in these
patients has been established. The role of thrombocytosis is still
debated,3 though recent evidence shows that a reduction in
platelet count is associated with decreased thrombotic risk in ET
patients receiving hydroxyurea.4 Numerous platelet defects
have also been identified, including abnormal platelet morphology,
acquired storage pool disease, platelet membrane abnormalities, and
abnormal arachidonic acid metabolism.5 Causal
relationships between any of these specific abnormalities and either
bleeding or thrombosis have not been clearly established.6 In contrast to red blood cells and platelets, no studies have been
conducted on white blood cells (WBCs), which can potentially be
involved in the thrombotic diathesis of these patients. Increases in
WBC count, typical of most patients with ET and PV, can be important in
the pathogenesis of a thrombophilic state. As reported by epidemiologic
studies in patients with coronary heart and peripheral arterial
diseases, high WBC count is associated with enhanced thrombotic
risk.7,8 Besides the cell count, numerous
polymorphonuclear leukocyte (PMN) functions can be relevant for the
hemostatic system activation and are potentially implicated in
thrombogenesis and endothelium damage.9 Activated PMNs
release reactive oxygen species and intracellular proteases, which can
act on endothelial cells and platelets and may modify the hemostatic
balance toward a pro-thrombotic state. Indeed leukocyte elastase and
cathepsin G can induce detachment or lysis of endothelial cells and can also modify endothelial cell functions involved in
thromboregulation10-13 Therefore, this study was designed to evaluate, in patients with ET and
PV, the in vivo activation features of circulating PMNs and the
concurrent variations in plasma hemostatic variables. For the first
time, we report on measurements of PMN phenotypical changes and
degranulation parameters in vivo in these patients9; we
also report on a series of parameters reflecting perturbation of the
endothelium and activation of blood coagulation in vivo.19
Patients
Twenty-two patients (12 with ET, 10 with PV) were not receiving any
treatment for ET or PV. Twenty-six patients (13 with ET, 13 with PV)
were administered hydroxyurea (HU), 12 patients (8 with ET, 4 with PV)
were administered HU and aspirin, 5 patients (4 with ET, 1 with PV)
were administered aspirin, and 6 patients with PV underwent phlebotomy
3 or more times a year. Five patients (3 with ET, 2 with PV) had had
thrombotic manifestations in the past; 3 of those had severe cerebral
ischemic attacks.
Samples
Whole blood was used for the cytofluorometric evaluation of CD11b and leukocyte alkaline phosphatase expression by PMN surface. PMNs for the analysis of cellular elastase content were isolated from citrated fresh venous blood immediately after venipuncture by density-gradient centrifugation, as described.10 The PMN fraction separated in the pellet was further purified from erythrocytes by dextrane erythrocyte sedimentation. Isolated PMNs were resuspended (106 cell/mL) in 10 mmol/L HEPES-Tyrode buffer (pH 7.4) containing 129 mmol/L NaCl, 9.9 mmol/L NaHCO3, 2.8 mmol/L KH2PO4, 0.8 mmol/L MgCl2-6H2O, and 1 mmol/L CaCl2. Cell viability was assessed by the trypan-blue exclusion dye test and was found to be greater than 90%. Cell suspensions contained more than 95% PMNs. Routine hematologic assays White blood cell (WBC) differential count, hematocrit, hemoglobin, red blood cell (RBC), and platelet counts were determined by automated methods using an NE800 Analyser (Dasit, Milan, Italy).PMN study PMN membrane CD11b and LAP. The expression of CD11b and LAP antigens was measured in whole blood by cytofluorometric analysis. For CD11b analysis, blood samples were incubated with phycoerythrin (PE)-conjugated mouse antihuman CD11b mAb (Becton Dickinson, Mountain View, CA) or with isotype-identical negative control mAb (IgG2a PE; Becton Dickinson). For LAP analysis, samples were incubated with mouse antihuman LAP (mAb 1B12.1) and stained with fluorescein isothiocyanate-conjugated goat-antimouse IgG (10 µg/mL, final concentration; Becton Dickinson).22 Samples were analyzed by a FACScan flow cytometer (Becton Dickinson). PMNs were selectively gated using their forward- and side-scatter properties, and 5000 PMN-gated events were measured for each sample. Acquisition and processing of data were performed with the CellQuest software (Becton Dickinson). Results are expressed as mean fluorescence intensity (MFI units), representing the mean level of marker expression/cell, or as percentage positive cells, representing the number of cells positive for the marker. CD11b is preferentially expressed as MFI units because CD11b antigen is constitutively expressed by 100% of the PMNs gated,23 and the number of molecules/cell increases on activation.24 Instead, LAP is expressed as percentage positive cells because LAP antigen is not expressed by all PMNs and a greater number of cells become positive on activation.25 PMN cellular elastase activity assay. Elastase activity was tested to quantify the enzyme content of PMNs. Activity was measured in cell lysates (106 cell/mL) by monitoring the rate of release of p-nitroanilide from the specific chromogenic substrate N-succinyl-Ala-Ala-Val-p-nitroanilide (Sigma Chemicals, St Louis, MO) at 410 nm.26 The activity of the samples (ng/106 cells) was extrapolated from a standard curve of known concentrations of human purified elastase (Sigma). Assay of PMN response to in vitro activation by stimulus. This test evaluates the capacity of PMNs to increase surface CD11b and LAP antigen expression on stimulus. Selected PMN samples from patients with ET (n = 16) and PV (n = 18) and control subjects (n = 20) were stimulated in vitro with N-formyl-Met-Leu-Phe (fMLP; Sigma). Specifically, whole blood was incubated in the aggregometer for 5 minutes at 37°C with 0.1 µmol/L fMLP (final concentration) or control buffer, under constant stirring (1000 rpm). Then samples were stained with anti-CD11b and anti-LAP mAb, as described above. Expression of CD11b and LAP antigens by PMN membranes of stimulated and unstimulated (control) samples was assayed by flow cytometry. Plasma markers of PMN activation Elastase and myeloperoxidase antigens were the plasma markers used to test the release of PMN azurophil granule content.27 Elastase coupled to its natural inhibitor 1-antitrypsin (1-AT) was detected in plasma as elastase-1-AT
complex by an immunoassay procedure (PMN Elastase IMAC; Merck,
Darmstadt, Germany). Plasma MPO was measured by enzyme-linked
immunosorbent assay (ELISA) using a commercial kit (Bioxytech MPO,
Enzyme Immunoassay; Oxis-International, Portland, OR).
Plasma markers of endothelial cell activation The parameters of endothelium damage studied were the plasma concentrations of thrombomodulin (TM) and von Willebrand factor (vWF).28 TM is the endothelial membrane receptor for thrombin.29 vWF is a multimeric protein synthesized and released from endothelial cells.30 Plasma TM antigen was quantitated using an ELISA kit from Diagnostica Stago (Roche Diagnostics, Monza, Italy) according to the manufacturer's instructions. Plasma vWF antigen (vWF:Ag) was determined by an electro-immunodiffusion procedure using reagents from Diagnostica Stago (Assera-Plate vWF; Roche Diagnostics). Results are expressed as percentage vWF, by comparison with a standard curve constructed with known dilutions of pooled normal plasma (made by the plasma samples from 20 healthy persons not receiving any medication). The undiluted plasma pool consisted of 100% vWF; vWF of the control group ranged from 60% to 150%.Plasma markers of hypercoagulation As markers of in vivo clotting activation, the plasma levels of prothrombin fragment F1 + 2 (F1 + 2), thrombin-antithrombin (TAT) complex, and D-dimer were measured. These are enzyme-inhibitor complexes or byproducts of the coagulation reactions, liberated during clotting activation, that provide a biochemical tool for the definition of the hypercoagulable state and are modulated by therapy.19,31 Plasma F1 + 2 and TAT complex concentrations were determined by ELISA, using commercially available kits (Enzygnost F1 + 2 and Enzygnost TAT, respectively; DADE Behring, Milan, Italy). Plasma D-dimer levels were determined by a commercial ELISA kit (Asserachrom D-dimer; Roche Diagnostics).Statistical analysis The Mann-Whitney U test was used to assess the significance of differences between the mean baseline values of the patient group versus the healthy control group. The Wilcoxon test was used to test the significance of within-group differences.Differences were considered significant at P < .05. Regression analysis was performed by the least-squares method, and the correlation coefficient (r2) was calculated.
Routine hematologic parameters As shown in Table 1, WBC, PMN, and platelet counts of patients with ET and PV were significantly greater than those of the control subjects. In patients with PV, RBC counts and hematocrit and hemoglobin levels also were significantly greater than those of the control subjects (P < .01). The lower range limits of some parameters particularly RBCs, platelets, hemoglobin, and
hematocritin patients was below the lower limits of normal control
range values. These results corresponded to those from patients
on cytoreductive therapy. The same was true of some patients with ET,
who had normal platelet counts (range,
360-1600 × 109/L). However, no influence of HU therapy
was observed in any of the parameters of PMN, endothelial, or clotting
activation here studied. One exception was the vWF level, which
appeared to be higher in non-HU-treated than in HU-treated subjects in
the ET group (non-HU vs HU, 214% ± 16% vs 163% ± 9.4%;
P < .05).
PMN study CD11b and LAP.
The expression of CD11b by PMNs in patients with ET and PV was
significantly greater than control subjects' values (C, 112 ± 11
MFI units; ET, 185 ± 20 MFI units, P < .01; PV,
187 ± 15 MFI units, P < .01). The percentage of
LAP-positive PMNs in patients with PV (73% ± 4.4% positive cells)
also was significantly greater than that in patients with ET
(63% ± 6.7% positive cells) and in control subjects
(41% ± 2.3% positive cells) (P < .01) (Figure 1).
Cellular elastase activity. To evaluate whether PMN cells also had different elastase contents, the elastase activity of PMN lysates was measured. As shown in Figure 1, there was a significant elevation of this enzyme activity in PMNs isolated from patients with PV (606 ± 52 ng/106 cells; P < .01) and ET (585 ± 45 ng/106 cells; P < .05) compared with controls (442 ± 46 ng/106 cells). In vitro PMN response.
This assay evaluates the capacity of PMNs to express CD11b and
LAP surface antigens after an activating stimulus (Figure
2). As demonstrated by preliminary
experiments, in vitro stimulation of normal control PMNs with
increasing concentrations of fMLP (from 0 to 10 µmol/L) significantly
increased the expression of CD11b and LAP by the PMN membrane, peaking
at 0.1 µmol/L fMLP (data not shown). Stimulation of patients' PMNs
with 0.1 µmol/L fMLP significantly increased CD11b and LAP expression
compared with unstimulated PMN counterparts. However, the mean
percentage increment ([value of stimulated sample
Plasma marker of PMN activation Plasma elastase and MPO antigens are the markers of PMN azurophil granule content release into the bloodstream. As shown in Figure 3 (upper panels), the plasma concentration of these markers was significantly increased (P < .01) in the circulation of both groups of patients compared with control subjects (elastase: ET, 63.7 ± 6.3 µg/L; PV, 86.1 ± 13.3 µg/L; C, 33.8 ± 2.2 µg/L; MPO: ET, 0.9 ± 1.5 µg/L; PV, 11.8 ± 1.5 µg/L; C, 4.2 ± 0.6 µg/L). Because patients and control subjects had different WBC counts, results were also corrected for the WBC count. The ratio (elastase or MPO antigen concentration [µg/L]/WBC count (109/L)]) was calculated for each patient and control subject. After correction, the differences between patients and controls persisted and were statistically significant (Figure 3, lower panels).
Plasma endothelial cell activation markers A significant increment of the circulating endothelial cell marker vWF:Ag was observed in the ET and PV groups (Figure 4) (ET, 188% ± 15%; PV, 180% ± 12%; C, 105% ± 13%). TM was augmented, though not significantly, in patients with ET (39 ± 5 ng/mL), but it was significantly increased in patients with PV (57 ± 8 ng/mL, P < .01) compared with controls (27 ± 2 ng/mL).
Plasma markers of hypercoagulation As shown in Figure 5, patients with ET and PV showed significantly higher values of plasma F1 + 2 (ET, 1.67 ± 0.14 nmol/L; PV, 1.87 ± 0.19 nmol/L; C, 1.1 ± 0.06 nmol/L) and TAT complex (ET, 5.15 ± 0.34 µg/L; PV, 4.97 ± 0.41 µg/L; C, 3.4 ± 0.31 µg/L) compared with controls. Levels of D-dimer were found significantly (P < .05) elevated only in the PV group (0.30 ± 0.03 µg/mL) compared with both the control (0.24 ± 0.02 µg/mL) and the ET (0.26 ± 0.04 µg/mL) groups.
Recent studies indicate an important role for PMN cells in triggering hemostatic system reactions. In this study, we investigated PMN activation status in patients with ET and PV and the occurrence of concomitant laboratory signs of endothelium or clotting activation, or both. Thirty-seven patients with ET and 34 with PV were studied. Results were compared with those of control subjects. In all patients, median RBC, WBC, PMN, and platelet counts were significantly increased over the values of controls (Table 1), as expected. In addition, median hematocrit and hemoglobin levels were significantly increased in the PV group. However, in some patients, the above parameters (particularly RBC, hematocrit, and hemoglobin) were low because of HU cytoreductive treatment. No influence of HU therapy on any of the parameters included in this study was observed. The only exception was the level of vWF in the ET group, which actually was lower in HU-treated patients. For this reason, we did not separate the results obtained from patients of either group on the basis of treatment. This study provides the first evidence of a significant in vivo PMN activation in patients with ET or PV. As markers of PMN activation, phenotypical changes (ie, increased CD11b and LAP expression on PMN surface) were measured. An increase in CD11b is currently accepted as a marker of PMN activation in vivo.9,24,25 Increments of LAP can be a feature of cellular activation as well. In fact, in this paper, we show that in vitro stimulation of normal PMNs by fMLP significantly increases the surface expression of LAP antigen. The question may arise as to whether the increments measured are somehow related to the different PMN counts. This is ruled out by the fact that the membrane CD11b and LAP values are expressed as MFI units or as percentage positive cells, respectively, which are calculated on a standard number of cells for each sample. Therefore, the changes detected correspond to activation changes per cell unit. Further, the elastase content held in the circulating PMNs was increased in the 2 groups of patients compared to the control group. These data are comparable between different subjects because cellular elastase is determined on cell lysates prepared from the same number of cells and is expressed as ng/106 cells. The finding of increased PMN elastase content in patients with ET and PV indicates a cellular abnormality possibly explained by the rapid turnover of these cells, with an increased proportion in the circulation of young PMNs containing more elastase. This interpretation is corroborated by the previous observation of an increased amount of elastase in PMNs from healthy subjects after an initial dose of granulocyte-colony stimulating factor (G-CSF).9 The increased basal levels of CD11b and LAP, together with the lower up-regulation of both markers after fMLP stimulation in vitro, in patients and not in control subjects strongly supports the conclusion that PMNs underwent granule secretion in vivo in patients with ET and PV. In patients' circulation we measured elevated levels of elastase and MPO, which represent 2 parameters of PMN degranulation and may be considered additional signs of activation of these cells in vivo. Although their concentrations also depend on the number of circulating WBCs,9,31 we found that, after normalization for the WBC count, the values of both elastase and MPO of patients with ET and PV remained greater than those of the control group. This finding supports the hypothesis of the occurrence of a cellular activation. As mentioned in the "Introduction," several intracellular PMN enzymes, including elastase, MPO and cathepsin G, have been shown to act on the coagulation and endothelial systems in vitro.10-18,32 In the previously mentioned study of PMN activation in healthy donors receiving G-CSF,9 we found a positive correlation between plasma elastase level and the levels of some markers of endothelial and clotting activation in vivo. In the current study the evaluation of 2 recognized plasma markers of activation/damage of endothelial cells shows that vWF and TM are significantly elevated in patients with ET and PV. It is possible to speculate that in this condition of endothelial perturbation, a role may be played, at least in part, by the abnormal levels of circulating PMN enzymes. In vitro evidences demonstrate that PMNs activated by various agonists (fMLP, bacterial endotoxin, cytokines) are able to damage monolayers of endothelial cells in culture.10,33,34 The damage goes from direct cytolysis and cell death, mediated by reactive species of the oxygen produced by activated PMNs, to the retraction and detachment of endothelial cells, mediated by proteases released by PMN granules. Among granule protease, elastase is the most involved in the pathogenesis of endothelial damage.35 The addition of purified elastase to the endothelium in vitro causes the detachment of endothelial cells in a dose-dependent manner. Endothelial cells in culture, incubated with activated PMNs or reactive species of oxygen, release vWF and TM in the culture medium.36,37 Furthermore, in this study, measurements of well-known plasma markers
of clotting system activation also indicated concomitant abnormalities
of TAT complex, F1 + 2, and D-dimer in the patient population. This
finding is in agreement with our previous observation of a
hypercoagulable state in a group of patients with ET.38 It
could in part be explained by the known hypercoagulable condition associated with malignancy,39 but PMN enzyme involvement
is possible. In vitro studies have shown evidence that elastase can proteolytically inactivate several physiological inhibitors of blood
coagulation Other authors have not confirmed the evidence of abnormalities of the plasma levels of endothelial cell damage markers in patients with ET.44 In that study, TM and vWF levels were increased in patients and not in controls without reaching statistical significance. In our study, we obtained similar results concerning TM levels in the ET group, but the concentration of vWF antigen was confirmed to be statistically greater in patients than in controls. We cannot explain this discrepancy, but published data describe increased vWF antigen levels in association with a history of thrombosis in patients with chronic myeloproliferative disorders.45 In conclusion, in this study, we observed the occurrence of granulocyte activation in association with laboratory abnormalities of clotting activation and endothelium perturbation in patients with 2 hematologic conditions who were at high risk for thrombosis. These results suggest that PMNs may be involved in the pathogenesis of the thrombophilic state in patients with ET and PV. The increase in WBC count, typical of most patients with these disorders, raises the possibility that the number of circulating leukocytes can be involved, as in other clinical conditions (eg, coronary heart and peripheral arterial diseases).7,8 However, the activation status of these cells is important because activated leukocytes have multiple interactions with platelets and vessel walls. In the in vivo model of healthy subjects administered G-CSF,9 the levels of PMN activation markers significantly correlated with the levels of either endothelium or clotting activation markers. We hypothesize that in addition to high hematocrit and blood viscosity levels, as in PV, or thrombocytosis and platelet abnormalities, as in ET, concurrent factors may be required for the onset of a thrombotic event in patients with ET and PV. PMN-related prothrombotic activity may be one of these factors. We did not find any association between the elevation of any of the markers analyzed and a history of thrombosis. This might likely be due to the limited number of subjects here analyzed. Further studies of patients followed in a prospective manner are needed to establish whether one or more of these parameters can be predictive of thrombosis in these conditions.
Submitted February 29, 2000; accepted August 30, 2000.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Anna Falanga, Hematology Division, Ospedali Riuniti Bergamo, Largo Barozzi, 1-24128 Bergamo, Italy; e-mail: annafalanga{at}yahoo.com.
1.
Schafer AI.
Bleeding and thrombosis in myeloproliferative disorders.
Blood.
1984;64:1-12
2.
Gruppo Italiano Studio Policitemia (GISP).
Polycythemia vera: the natural history of 1213 patients followed over 20 years.
Ann Intern Med.
1995;123:656-664 3. Barbui T, Finazzi G. Risk factors and prevention of vascular complications in polycythemia vera. Semin Thromb Hemost. 1997;23:455-461[Medline] [Order article via Infotrieve].
4.
Cortelazzo S, Finazzi G, Ruggeri M, et al.
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.
N Engl J Med.
1995;332:1132-1136 5. Cortelazzo S, Marchetti M, Orlando E, Falanga A, Barbui T, Buchanan MR. Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lypoxygenase pathway. Am J Hematol. 1998;57:277-282[Medline] [Order article via Infotrieve]. 6. Finazzi G, Budde U, Michiels JJ. Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative disorders. Leuk Lymphoma. 1996;22(suppl 1):72-78.
7.
Danesh J, Collins R, Appleby P, Peto R.
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies.
JAMA.
1998;279:1477-1482
8.
Lowe G, Fowkes F, Dawes J, Donnan P, Lennie S, Housley E.
Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburg Artery Study.
Circulation.
1983;87:1915-1920
9.
Falanga A, Marchetti M, Evangelista V, et al.
Neutrophil activation and hemostatic changes in healthy donors given granulocyte-colony stimulating factor.
Blood.
1999;93:2506-2514 10. Harlan JM, Killen PD, Harken LA, Striker GE, Wright DG. Neutrophil-mediated endothelial injury in vitro: mechanisms of cell detachment. J Clin Invest. 1981;68:1394-1403. 11. Kolpakov V, D'Adamo MC, Salvatore L, et al. Neutrophil-derived cathepsin G induces potentially thrombogenic changes in human endothelial cells: a scanning electron microscopy study in static and dynamic conditions. Thromb Haemost. 1994;72:140-145[Medline] [Order article via Infotrieve].
12.
Weksler BB, Jaffe EA, Brower MS, Cole OF.
Human leukocyte cathepsin G and elastase specifically suppress thrombin-induced prostacyclin production in human endothelial cells.
Blood.
1989;74:1627-1634 13. Pintucci G, Iacoviello L, Castelli MP, et al. Cathepsin G-induced release of PAI-1 in the culture medium of endothelial cells: a new thrombogenic role for polymorphonuclear leukocytes? J Lab Clin Med. 1993;122:69-79[Medline] [Order article via Infotrieve].
14.
Evangelista V, Piccardoni P, White JG, de Gaetano G, Cerletti C.
Cathepsin G-dependent platelet stimulation by activated polymorphonuclear leukocytes and its inhibition by antiproteinases: role of P-selectin-mediated cell-cell adhesion.
Blood.
1993;81:2947-2957 15. Eckle I, Seitz R, Egbring R, Kolb G, Havemann K. Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe-Seyler. 1991;372:1007-1013[Medline] [Order article via Infotrieve]. 16. Eckle I, Seitz R, Egbring R, Kolb G, Havemann K. Protein S degradation in vitro by neutrophil elastase. Scand J Clin Lab Invest. 1993;53:281-288[Medline] [Order article via Infotrieve].
17.
Higuchi DA, Wun TC, Likert KM, Broze GJ.
The effect of leukocyte elastase on tissue factor pathway inhibitor.
Blood.
1992;79:1712-1719
18.
Jordan RE, Kilpatrick J, Nelson RM.
Heparin promotes the inactivation of antithrombin by neutrophil elastase.
Science.
1987;237:777-779 19. Falanga A, Levine MN, Consonni R, et al. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial. Thromb Haemost. 1998;79:23-27[Medline] [Order article via Infotrieve]. 20. Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol. 1975;12:409-430[Medline] [Order article via Infotrieve]. 21. Berlin NI. Diagnosis and classification of the polycythemia. Semin Hematol. 1975;12:339-351[Medline] [Order article via Infotrieve]. 22. Rambaldi A, Masuhara K, Borleri GM, et al. Flow cytometry of leukocyte alkaline phosphatase in normal and pathologic haemapoietic cell. Br J Haematol. 1997;96:815-822[Medline] [Order article via Infotrieve]. 23. Terstappen LWMM, Safford M, Loken MR. Flow cytometric analysis of human bone marrow III: neutrophil maturation. Leukemia. 1990;4:657-663[Medline] [Order article via Infotrieve].
24.
Kuijpers TW, Tool ATJ, van der Schoot CE, et al.
Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers of neutrophil activation.
Blood.
1991;78:1105-1111
25.
van Pelt LJ, Huisman MV, Weening RS, von dem Borne AEGKR, Roos D, van Oers RHJ.
A single dose of granulocyte-macrophage colony-stimulating factor induces systemic interleukin-8 release and neutrophil activation in healthy volunteers.
Blood.
1996;87:5305-5313
26.
Renesto P, Chignard M.
Enhancement of cathepsin G-induced activation by leukocyte elastase: consequence for the neutrophil-mediated platelet activation.
Blood.
1993;82:139-144 27. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood Rev. 1997;89:3503-3521. 28. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol. 1995;90:244-248[Medline] [Order article via Infotrieve].
29.
Dittman WA, Majerus PW.
Structure and function of thrombomodulin: a natural anticoagulant.
Blood.
1990;75:329-336
30.
Ruggeri ZM, Zimmerman TS.
The complex multimeric composition of factor VIII/von Willebrand factor.
Blood.
1981;57:1140-1143
31.
Falanga A, Iacoviello L, Evangelista V, et al.
Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia given all-trans-retinoic acid.
Blood.
1995;86:1072-1081 32. Clark RA, Klebanoff SJ. Neutrophil-platelet interaction mediated by myeloperoxidase and hydrogen peroxidase. J Immunol. 1980;124:399-405[Medline] [Order article via Infotrieve]. 33. Smedly LA, Tonnesen MG, Sandhaus RA, et al. Neutrophil-mediated injury to endothelial cells: enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest. 1986;77:1233-1243. 34. Martin WJ. Neutrophils kill pulmonary endothelial cells by a hydrogen-peroxide-dependent pathway: an in vitro model of neutrophil-mediated lung injury. Am Rev Respir Dis. 1984;130:209-213[Medline] [Order article via Infotrieve]. 35. Westlin WF, Gimbrone MA. Neutrophil-mediated damage to human vascular endothelium. Am J Pathol. 1993;142:117-128[Abstract]. 36. Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost. 1991;65:618-623[Medline] [Order article via Infotrieve].
37.
Vischer UM, Jornot L, Wolleheim CB, Theler JM.
Reactive oxygen intermediates induce regulated secretion of von Willebrand factor from cultured human vascular endothelial cells.
Blood.
1995;85:3164-3172 38. Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Marziali S, Barbui T. Hemostatic system activation in patients with lupus anticoagulant and essential thrombocythemia. Semin Thromb Hemost. 1994;20:324-327[Medline] [Order article via Infotrieve]. 39. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in cancer patients. Semin Thromb Hemost. 1999;25:173-182[Medline] [Order article via Infotrieve]. 40. Camire RM, Kalafatis M, Tracy PB. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding. Biochemistry. 1998;37:11896-11906[Medline] [Order article via Infotrieve].
41.
Owen CA, Campbell MA, Sannes PL, Boukedes SS, Campbell EJ.
Cell surface-bound elastase and cathepsin G on human neutrophils focus and preserve catalytic activity of serine proteinases.
J Cell Biol.
1995;131:775-789 42. Weiss SJ. Tissue distruction by neutrophils. N Engl J Med. 1989;320:365-376[Medline] [Order article via Infotrieve].
43.
Evangelista V, Manarini S, Rotondo S, et al.
Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: evidence of adhesion cascade and cross-talk between P-selectin and the 44. Bellucci S, Ignatova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, tPA and vWF. Thromb Haemost. 1993;70:736-742[Medline] [Order article via Infotrieve]. 45. Friedenberg WR, Roberts RC, David DE. Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. Am J Hematol. 1992;40:283-289[Medline] [Order article via Infotrieve].
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  F. Cervantes, E. Arellano-Rodrigo, and A. Alvarez-Larran Blood cell activation in myeloproliferative neoplasms Haematologica, November 1, 2009; 94(11): 1484 - 1488. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Barbui, A. Carobbio, A. Rambaldi, and G. Finazzi Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood, July 23, 2009; 114(4): 759 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Marchetti, E. Castoldi, H. M. H. Spronk, R. van Oerle, D. Balducci, T. Barbui, J. Rosing, H. ten Cate, and A. Falanga Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera Blood, November 15, 2008; 112(10): 4061 - 4068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Landolfi and L. Di Gennaro Prevention of thrombosis in polycythemia vera and essential thrombocythemia Haematologica, March 1, 2008; 93(3): 331 - 335. [Full Text] [PDF]
|
|
|
|
|
|
A. L Basquiera, F. Fassetta, N. Soria, J. M. Barral, B. Ricchi, and J. J Garcia Accuracy of leukocyte alkaline phosphatase score to predict JAK2 V617F mutation Haematologica, May 1, 2007; 92(5): 704 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Landolfi, L. Di Gennaro, T. Barbui, V. De Stefano, G. Finazzi, R. Marfisi, G. Tognoni, R. Marchioli, and for the European Collaboration on Low-Dose Aspirin Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera Blood, March 15, 2007; 109(6): 2446 - 2452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Carobbio, G. Finazzi, V. Guerini, O. Spinelli, F. Delaini, R. Marchioli, G. Borrelli, A. Rambaldi, and T. Barbui Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status Blood, March 15, 2007; 109(6): 2310 - 2313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Steensma and R. E. Richard Myeloproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 172 - 227. [Full Text] [PDF]
|
|
|
|
 |
|
 T. G.P. Bumm, C. Elsea, A. S. Corbin, M. Loriaux, D. Sherbenou, L. Wood, J. Deininger, R. T. Silver, B. J. Druker, and M. W.N. Deininger Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease Cancer Res., December 1, 2006; 66(23): 11156 - 11165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M R Ray, S Mukherjee, S Roychoudhury, P Bhattacharya, M Banerjee, S Siddique, S Chakraborty, and T Lahiri Platelet activation, upregulation of CD11b/CD18 expression on leukocytes and increase in circulating leukocyte-platelet aggregates in Indian women chronically exposed to biomass smoke Human and Experimental Toxicology, November 1, 2006; 25(11): 627 - 635. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Heinicke, O. Baum, O. O. Ogunshola, J. Vogel, T. Stallmach, D. P. Wolfer, S. Keller, K. Weber, P. D. Wagner, M. Gassmann, et al. Excessive erythrocytosis in adult mice overexpressing erythropoietin leads to hepatic, renal, neuronal, and muscular degeneration Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2006; 291(4): R947 - R956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hoffman and M. Xu Is bone marrow fibrosis the real problem? Blood, May 1, 2006; 107(9): 3421 - 3422. [Full Text] [PDF]
|
|
|
|
|
|
F. Passamonti, E. Rumi, D. Pietra, M. G. D. Porta, E. Boveri, C. Pascutto, L. Vanelli, L. Arcaini, S. Burcheri, L. Malcovati, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders Blood, May 1, 2006; 107(9): 3676 - 3682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. O. Ogunshola, V. Djonov, R. Staudt, J. Vogel, and M. Gassmann Chronic excessive erythrocytosis induces endothelial activation and damage in mouse brain Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R678 - R684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Campbell and A. R. Green The Long-term Outlook for Essential Thrombocythemia Mayo Clin. Proc., February 1, 2006; 81(2): 157 - 158. [Full Text] [PDF]
|
|
|
|
|
|
A. P. Wolanskyj, S. M. Schwager, R. F. McClure, D. R. Larson, and A. Tefferi Essential Thrombocythemia Beyond the First Decade: Life Expectancy, Long-term Complication Rates, and Prognostic Factors Mayo Clin. Proc., February 1, 2006; 81(2): 159 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kralovics, S.-S. Teo, A. S. Buser, M. Brutsche, R. Tiedt, A. Tichelli, F. Passamonti, D. Pietra, M. Cazzola, and R. C. Skoda Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 Blood, November 15, 2005; 106(10): 3374 - 3376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Harrison, P. J. Campbell, G. Buck, K. Wheatley, C. L. East, D. Bareford, B. S. Wilkins, J. D. van der Walt, J. T. Reilly, A. P. Grigg, et al. Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia N. Engl. J. Med., July 7, 2005; 353(1): 33 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Barbui and G. Finazzi When and How to Treat Essential Thrombocythemia N. Engl. J. Med., July 7, 2005; 353(1): 85 - 86. [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Harrison Platelets and Thrombosis in Myeloproliferative Diseases Hematology, January 1, 2005; 2005(1): 409 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J A Zeller, K Frahm, R Baron, R Stingele, and G Deuschl Platelet-leukocyte interaction and platelet activation in migraine: a link to ischemic stroke? J. Neurol. Neurosurg. Psychiatry, July 1, 2004; 75(7): 984 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Finazzi, M. Ruggeri, F. Rodeghiero, and T. Barbui Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis Blood, May 1, 2003; 101(9): 3749 - 3749. [Full Text] [PDF]
|
|
|
|
|
|
A. Tefferi Polycythemia Vera: A Comprehensive Review and Clinical Recommendations Mayo Clin. Proc., February 1, 2003; 78(2): 174 - 194. [Abstract] [PDF]
|
|
|
|
|
|
J. L. Spivak Polycythemia vera: myths, mechanisms, and management Blood, December 15, 2002; 100(13): 4272 - 4290. [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Lopes, L. H. Caramuru, and N. Y. Maeda Endothelial Dysfunction Associated with Chronic Intravascular Coagulation in Secondary Pulmonary Hypertension Clinical and Applied Thrombosis/Hemostasis, October 1, 2002; 8(4): 353 - 358. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
80°C until assays (within 2 months).
2 integrin CD11b/CD18.
Blood.
1996;88:4185-4194.